Cyclin E-CDK2 is a regulator of p27(Kip1)

Genes and Development

Volumn 11, Issue 11, 1997, Pages 1464-1478

  Sheaff, Robert J ^a   Groudine, Mark ^a,c   Gordon, Matthew ^a   Roberts, James M ^a   Clurman, Bruce E ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

CDK; Cell cycle; Cyclin; p27(Kip1)

Indexed keywords

CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN E;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN 3T3; CONTROLLED STUDY; ENZYME INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALIA; MURINAE;

EID: 0030925231     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.11.11.1464     Document Type: Article

References (52)

1. Agrawal, D., P. Hauser, F. McPhersen, F. Dong, A. Garcia, and W.J. Pledger. 1996. Repression of p27kip 1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. Mol Cell. Biol. 16: 4327-4336.
2. Boyle, W.J., P. Van Der Geer, and T. Hunter. 1991. Phosphopeptide mapping and phosphoamino acid analysis by two-dimensional separation on thin-layer chromotography plates. Methods Enzymol. 201: 110-148.
3. Bresnahan, W.A., I. Boldogh, T. Ma, T. Albrecht, and E.A. Thompson. 1996. Cyclin E/CDK2 activity is controlled by different mechanisms in the G0 and G1 phases of the cell cycle. Cell Growth Differ. 7: 1283-1290.
4. Clurman, B.E., J.M. Roberts, and M. Groudine. 1996a. Deregulation of cell cycle control in hematologic malignancies. Curr. Opin. Hematol. 3:315-320.
5. Clurman, B.E., R. Sheaff, K. Thress, M. Groudine, and J. Roberts. 1996b. Turnover of cyclin E by the ubiquitin-proteasome pathway is regulated by CDK2 binding and cyclin phosphorylation. Genes & Dev. 10: 1979-1990.
6. Coats, S., W.M. Flannagan, J. Nourse, and J. Roberts. 1996. Requirement of p27Kip1 for restriction point control of the fibroblast cell cycle. Science 272: 877-880.
7. CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. Cell 82: 675-684.
8. Dulic, V., W. Kaufman, S. Wilson, T. Tlsty, E. Lees, J.W. Harper, S. Elledge, and S. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023.
9. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.B. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
10. Fang, G., N. Orend, T. Watanabe, T. Hunter and E. Ruoslahti. 1996. Dependence of cyclin E-CDK2 kinase activity on cell anchorage. Science 271: 499-502.
11. Fero, M.L., M. Rivkin, M. Tasch, P. Porter, C.E. Carow, E. Firpo, K. Polyak, L. Tsai, V. Broudy, R.M. Perlmutter, K. Kaushansky, and J.M. Roberts. 1996. A syndrome of multi-organ hyperplasia with features of gigantism, tumorigenesis and female sterility in p27 kip 1-deficient mice. Cell 85: 733-744.
12. Firpo, E.J., A. Koff, M. Solomon, and J. Roberts. 1994. Inactivation of a CDK2 inhibitor during Interleukin 2-induced proliferation of human T lymphocytes Mol. Cell. Biol. 14: 4889-4901.
13. Fersht, A. 1984. Enzyme structure and mechanism. W.H. Freeman, New York, NY.
14. Gu, Y., C. Turek, and D. Morgan. 1993. Inhibition of CDK2 activity in vivo by an associated 20K regulatory subunit. Nature 366: 707-710.
15. Harper, J.W, G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 CDK-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
16. Hauschka, P.V. 1973. Analysis of nucleotide pools in animal cells. Methods Cell Biol. 7:361-462.
17. Hengst, L. and S.I. Reed. 1996. Translational control of p27Kip 1 accumulation during the cell cycle. Science 271: 1861-1864.
18. Hirai, H., M.F. Roussel, J.Y. Kato, R.A. Ashmun, and C.J. Sherr. 1995. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol. 15:2672-2681.
19. Hoffmann, I., G. Draetta, and E. Karsenti. 1994. Activation of the phosphatase activity of human cdc25A by a CDK2-cyclin E dependent phosphorylation at the G1/S transition. EMBO J. 13: 4302-4310.
20. Kamb, A. 1994. Role of a cell cycle regulator in hereditary and sporadic cancer. Cold Spring Harbor Symp. Quant. Biol. 49: 39-47.
21. Kato, J.M., M. Matsuoka, K. Polyak, J. Massague, and C.J. Sherr. 1994. Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase-4 activation. Cell 79: 487-496.
22. Kiyokawa, H., R.D. Kineman, K.O. Manova-Todorova, V.C. Soares, M. Ono, D. Khanam, A.C. Hayday, L.A. Frohman, and A. Koff. 1996. Enhanced growth of mice lacing the cyclin-dependent kinase inhibitor p27kip1. Cell 85: 721-732.
23. Koff, A., D. Giordano, K. Desai, W. Yamashita, W. Harper, S. Elledge, T. Nishimoto, D. Morgon, R. Franza, and J. Roberts. 1992. Formation and activation of a cyclin E-CDK2 complex during the G1 phase of the human cell cycle. Science 257: 1689-1693.
24. Koff, A., M. Ohtsuki, K. Polyack, J. Roberts, and J. Massague. 1993. Negative regulation of G1 in mammalian cells: Inhibition of cyclin E-dependent kinase by TGF-beta. Science 260: 536-539.
25. Kunkel, T.A., J. Roberts, and R. Zakour. 1987. Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol. 154: 367-382.
26. Cip1. Nature 375: 159-161.
27. Mendenhall, M. 1993. An inhibitor of p34 CDC28 protein kinase activity from Saccharomyces cerevisiae. Science 259: 216-219.
28. Morgan, D. 1995. Principles of CDK regulation. Nature 374: 131-144.
29. klp1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituatary tumors. Cell 85: 707-720.
30. Nobori, T., K. Miura, D.J. Wu, A. Lois, K. Takabayashi, and D.A. Carson. 1994. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368: 753-756.
31. Noda, A., Y. Ning, S. Venable, O. Pereira-Smith, and J. Smith. 1994. Cloning of senescent cell-derived inhibitors of DNA synthesis using an expression screen. Exp. Cell Res. 211: 90-98.
32. kip1 cyclin-CDK kinase inhibitor prevented by rapamycin. Nature 372: 570-573.
33. Pagano, M., S.W. Tam, A. Theodoras, P. Beer-Romero, G. Del Sal, V. Chau, R. Yew, G. Draetta, and M. Rolfe. 1995. Role of the ubiquitin proteosome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science 269: 682-685.
34. Polyak, K., M.H. Lee, H. Erdjument-Bromage, A. Koff, J.M. Roberts, P. Tempst, and J. Massague. 1994a. Cloning of p27 kip1: A cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell 78: 59-66.
35. kip1, a cyclin-CDK inhibitor, links transforming growth factor β and contact inhibition to cell cycle arrest. Genes &. Dev. 8: 9-22.
36. Quelle, D.E., R.A. Ashmun, G.J. Hannon, P.A. Rehberger, D. Trono, K.H. Richter, C. Walker, D. Beach, C.J. Sherr, and M. Serrano. 1995. Cloning and characterization of murine p16INK4a and p15INK4b genes. Oncogene 11: 635-645.
37. Roberts, J.M., A. Koff, K. Polyak, E. Firpo, S. Collins, M. Ohtsubo, and J. Massague. 1994. Cyclins, CDKs, and cyclin kinase inhibitors. Cold Spring Harbor Symp. Quant. Biol. 59: 31-38.
38. Russo, A.A., P.D. Jeffrey, A.K. Patten, J. Massague, and N.P. Pavletich. 1996. Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-CDK2 complex. Nature 382: 325-331.
39. Schneider, B., Y. Yang, and B. Futcher. 1996. Linkage of replication to start by the CDK inhibitor sic1. Science 272: 560-562.
40. Schwob, E., T. Bohm, M. Mendenhall, and K. Nasmyth. 1994. The B-type cyclins kinase inhibitor p40sicl controls the G1 to S phase transition in S. cerevisiae. Cell 79: 233-244.
41. Serrano, M., G. Hannon, and D. Beach. 1993. A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704-707.
42. Serrano, M., H. Lee, L. Chin, C. Cordon-Cardo, D. Beach, and R.A. DePinho. 1996. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85: 27-37.
43. Sherr, C. 1994. G1 phase progression: Cycling on cue. Cell 79: 551-555.
44. 1 cyclin-dependent kinases. Genes & Dev. 9: 1149-1153.
45. Slingerland, J., L. Hengst, C. Pan, D. Alexander, M.R. Stampfer, and S.I. Reed. 1994. A novel inhibitor of cyclin-CDK activity detected in transforming growth factor beta-arrested epithelial cells. Mol Cell. Biol. 14: 3683-3694.
46. Toyoshima, H. and T. Hunter. 1994. p27, a novel inhibitor of G1-cyclin-CDK protein kinase activity, is related to p21. Cell 78: 67-74.
47. van den Heuval, S. and E. Harlow. 1993. Distinct roles for cyclin-dependent kinases in cell cycle control. Science 262: 2050-2054.
48. Won, K. and S. Reed. 1996. Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J. 15: 4182-4193.
49. Xiong, Y., G. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993a. p21 is a universal inhibitor of cyclin kinases. Nature 366: 701-704.
50. Xiong, Y., H. Zhang, and D. Beach. 1993b. Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes & Dev. 7: 1572-1583.
51. CIP1-related domain to bind cyclin/CDK2 and regulate interactions with E2F. Genes & Dev. 9: 1740-1752.
52. Zhu, X., M. Ohtsubo, R.M. Bohmer, J.M. Roberts, and R. Assoian. 1996. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-CDK2 and phosphorylation of the retinoblastoma protein. J. Cell Biol. 133: 391-403.